title: Advancement in vaccination against Newcastle disease: recombinant HVT NDV provides high clinical protection and reduces challenge virus shedding with the absence of vaccine reactions.
abstract: Newcastle disease (ND) is a highly contagious disease of chickens causing significant economic losses worldwide. Due to the limitation in their efficacy, current vaccination strategies against ND need improvements. This study aimed to evaluate a new-generation ND vaccine for its efficacy in providing clinical protection and reducing virus shedding after challenge. Broiler chickens were vaccinated in ovo or subcutaneously at hatch with a turkey herpesvirus-based recombinant vaccine (rHVT) expressing a key protective antigen (F glycoprotein) of Newcastle disease virus (NDV). Groups of birds were challenged at 20, 27, and 40 days of age with a genotype V viscerotropic velogenic NDV strain. Protection was 57% and 81%, 100% and 95%, and 100% and 100% after the subsequent challenges in the in ovo and subcutaneously vaccinated chickens, respectively. Humoral immune response to vaccination could be detected from 3-4 wk of age. Challenge virus shedding was lower and gradually decreased over time in the vaccinated birds compared to the unvaccinated control chickens. In spite of the phylogenetic distance between the NDV F gene inserted into the vector vaccine and the challenge virus (genotype I and V, respectively), the rHVT NDV vaccine provided good clinical protection and significantly reduced challenge virus shedding.
authors.affiliation: Ceva-Phylaxia Veterinary Biologicals Co. Ltd., 1107 Budapest, Szállás u. 5. Hungary. vilmos.palya@ceva.com
authors.forename: V
authors.initials: V
authors.lastname: Palya
authors.forename: I
authors.initials: I
authors.lastname: Kiss
authors.forename: T
authors.initials: T
authors.lastname: Tatár-Kis
authors.forename: T
authors.initials: T
authors.lastname: Mató
authors.forename: B
authors.initials: B
authors.lastname: Felföldi
authors.forename: Y
authors.initials: Y
authors.lastname: Gardin
mesh_terms: D000281:Administration, Intranasal / Q000662:veterinary; D000367:Age Factors; D000818:Animals; D000914:Antibodies, Viral / Q000097:blood; D002642:Chick Embryo; D002645:Chickens; D006385:Hemagglutination Inhibition Tests / Q000662:veterinary; D026002:Herpesvirus 1, Meleagrid / Q000235:genetics; D008380:Marek Disease / Q000276:immunology / Q000517:prevention & control / Q000821:virology; D009521:Newcastle Disease / Q000276:immunology / Q000517:prevention & control* / Q000821:virology; D009522:Newcastle disease virus / Q000276:immunology*; D011201:Poultry Diseases / Q000276:immunology / Q000517:prevention & control* / Q000821:virology; D060888:Real-Time Polymerase Chain Reaction / Q000662:veterinary; D020133:Reverse Transcriptase Polymerase Chain Reaction / Q000662:veterinary; D014613:Vaccines, Attenuated / Q000008:administration & dosage / Q000235:genetics / Q000276:immunology; D014614:Vaccines, Synthetic / Q000008:administration & dosage / Q000276:immunology; D014760:Viral Fusion Proteins / Q000235:genetics / Q000276:immunology*; D014765:Viral Vaccines / Q000008:administration & dosage / Q000235:genetics / Q000276:immunology*; D017201:Virus Shedding
chemical_list: D000914:Antibodies, Viral; D014613:Vaccines, Attenuated; D014614:Vaccines, Synthetic; D014760:Viral Fusion Proteins; D014765:Viral Vaccines